175 related articles for article (PubMed ID: 19771930)
1. Shiatsu as an adjuvant therapy for schizophrenia: an open-label pilot study.
Lichtenberg P; Vass A; Ptaya H; Edelman S; Heresco-Levy U
Altern Ther Health Med; 2009; 15(5):44-6. PubMed ID: 19771930
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial.
Tang WK; Ungvari GS
Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):373-9. PubMed ID: 12691772
[TBL] [Abstract][Full Text] [Related]
3. Clinical response to clozapine treatment of 11 chronic patients in a state psychiatric hospital.
Herman M
Aust N Z J Ment Health Nurs; 1997 Sep; 6(3):129-33. PubMed ID: 9384012
[TBL] [Abstract][Full Text] [Related]
4. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
[TBL] [Abstract][Full Text] [Related]
5. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial.
Lerner V; Miodownik C; Gibel A; Kovalyonok E; Shleifer T; Goodman AB; Ritsner MS
Clin Neuropharmacol; 2008; 31(1):25-33. PubMed ID: 18303488
[TBL] [Abstract][Full Text] [Related]
6. Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study.
Levin FR; Evans SM; Coomaraswammy S; Collins ED; Regent N; Kleber HD
Am J Drug Alcohol Abuse; 1998 Aug; 24(3):343-60. PubMed ID: 9741939
[TBL] [Abstract][Full Text] [Related]
7. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
8. [Generic quetiapine in the treatment of acute schizophrenia and schizoaffective disorder].
György B; Robert K; László C; Andrea J;
Neuropsychopharmacol Hung; 2008 Dec; 10(5):293-303. PubMed ID: 19419015
[TBL] [Abstract][Full Text] [Related]
9. Effects of quetiapine on cognitive functions in schizophrenia.
Kivircik Akdede BB; Alptekin K; Kitiş A; Arkar H; Akvardar Y
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):233-8. PubMed ID: 15694229
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of auricular acupressure as an adjuvant therapy in substance abuse treatment: a pilot study.
Tian X; Krishnan S
Altern Ther Health Med; 2006; 12(1):66-9. PubMed ID: 16454149
[TBL] [Abstract][Full Text] [Related]
11. Adjunct extended-release valproate semisodium in late life schizophrenia.
Sajatovic M; Coconcea N; Ignacio RV; Blow FC; Hays RW; Cassidy KA; Meyer WJ
Int J Geriatr Psychiatry; 2008 Feb; 23(2):142-7. PubMed ID: 17582828
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
Lee KU; Jeon YW; Lee HK; Jun TY
Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
[TBL] [Abstract][Full Text] [Related]
13. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
[TBL] [Abstract][Full Text] [Related]
14. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility.
Citrome L; Shope CB; Nolan KA; Czobor P; Volavka J
Int Clin Psychopharmacol; 2007 Nov; 22(6):356-62. PubMed ID: 17917554
[TBL] [Abstract][Full Text] [Related]
15. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
[TBL] [Abstract][Full Text] [Related]
16. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine.
Delle Chiaie R; Salviati M; Fiorentini S; Biondi M
Exp Clin Psychopharmacol; 2007 Dec; 15(6):563-8. PubMed ID: 18179309
[TBL] [Abstract][Full Text] [Related]
17. Cognitive behaviour therapy for schizophrenia: relationship between anxiety symptoms and therapy.
Naeem F; Kingdon D; Turkington D
Psychol Psychother; 2006 Jun; 79(Pt 2):153-64. PubMed ID: 16774715
[TBL] [Abstract][Full Text] [Related]
18. Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study.
Yamada K; Watanabe K; Nemoto N; Fujita H; Chikaraishi C; Yamauchi K; Yagi G; Asai M; Kanba S
Psychiatry Res; 2006 Jan; 141(1):61-9. PubMed ID: 16318875
[TBL] [Abstract][Full Text] [Related]
19. [What impedes discharge support for persons with schizophrenia in psychiatric hospitals?].
Ikebuchi E; Satoh S; Anzai N
Seishin Shinkeigaku Zasshi; 2008; 110(11):1007-22. PubMed ID: 19202923
[TBL] [Abstract][Full Text] [Related]
20. Yi-gan san for the treatment of borderline personality disorder: an open-label study.
Miyaoka T; Furuya M; Yasuda H; Hayashia M; Inagaki T; Horiguchi J
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):150-4. PubMed ID: 17765378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
